EUCTR2011-001015-32-FI
Active, not recruiting
Phase 1
A prospective randomised Phase III trial to evaluate optimal treatment duration of first-line bevacizumabin combination with carboplatin and paclitaxel in patients with primary epithelial ovarian, fallopian tube or peritoneal cancer. - The BOOST (Bevacizumab Ovarian Optimal Standard Treatment) Trial - boost
Johanna Mäenpää0 sites796 target enrollmentMarch 12, 2012
ConditionsEpithelial ovarian cancer, fallopian tube carcinoma, primary peritoneal carcinoma, FIGO Stages IIb-IVMedDRA version: 14.1Level: LLTClassification code 10033130Term: Ovarian cancer NOSSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]
DrugsAvastin
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Epithelial ovarian cancer, fallopian tube carcinoma, primary peritoneal carcinoma, FIGO Stages IIb-IV
- Sponsor
- Johanna Mäenpää
- Enrollment
- 796
- Status
- Active, not recruiting
- Last Updated
- 5 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1\.2 Adults (18\-64 years) yes
- •F.1\.2\.1 Number of subjects for this age range 498
- •F.1\.3 Elderly (\>\=65 years) yes
- •F.1\.3\.1 Number of subjects for this age range 298
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 1
Evaluation of optimal initial treatment duration of bevacizumab in combination with carboplatin and paclitaxel in patients with ovarian cancer.Following primary cytoreductive surgery, patients with newly diagnosed FIGO stage IIB - IV (all grades and all histological types) epithelial ovarian cancer, fallopian tube carcinoma or primary peritoneal carcinomas with indication for a platin/paclitaxel chemotherapyMedDRA version: 14.0Level: PTClassification code 10033128Term: Ovarian cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2011-001015-32-FRAGO Research GmbH796
Active, not recruiting
Phase 1
Evaluation of optimal initial treatment duration of bevacizumab in combination with carboplatin and paclitaxel in patients with ovarian cancer.Following primary cytoreductive surgery, patients with newly diagnosed FIGO stage IIB - IV (all grades and all histological types) epithelial ovarian cancer, fallopian tube carcinoma or primary peritoneal carcinomas with indication for a platin/paclitaxel chemotherapyMedDRA version: 19.1Level: PTClassification code 10033128Term: Ovarian cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2011-001015-32-DKAGO Research GmbH796
Active, not recruiting
Phase 1
Evaluation of optimal initial treatment duration of bevacizumab in combination with carboplatin and paclitaxel in patients with ovarian cancer.Following primary cytoreductive surgery, patients with newly diagnosed FIGO stage IIB - IV (all grades and all histological types) epithelial ovarian cancer, fallopian tube carcinoma or primary peritoneal carcinomas with indication for a platin/paclitaxel chemotherapyMedDRA version: 20.0Level: PTClassification code 10033128Term: Ovarian cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2011-001015-32-DEAGO Research GmbH900
Recruiting
Phase 3
A randomised phase III trial evaluating the efficacy of more intensive written information in patients having radical radiation therapy.Anxiety levelsPatient satisfaction.Mental Health - AnxietyACTRN12605000705684Perth Radiation Oncology Centre212
Active, not recruiting
Not Applicable
A Phase III randomised, controlled trial of exercise during chemotherapy for patients commencing first line treatment for ovarian cancerOvarian CancerCancer - Ovarian and primary peritonealACTRN12614001311640niversity of Sydney524